GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bionano Genomics Inc (NAS:BNGO) » Definitions » Beneish M-Score

Bionano Genomics (Bionano Genomics) Beneish M-Score : -3.62 (As of Apr. 26, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Bionano Genomics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.62 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Bionano Genomics's Beneish M-Score or its related term are showing as below:

BNGO' s Beneish M-Score Range Over the Past 10 Years
Min: -3.62   Med: -2.18   Max: -0.73
Current: -3.62

During the past 8 years, the highest Beneish M-Score of Bionano Genomics was -0.73. The lowest was -3.62. And the median was -2.18.


Bionano Genomics Beneish M-Score Historical Data

The historical data trend for Bionano Genomics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bionano Genomics Beneish M-Score Chart

Bionano Genomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial - - -0.73 -2.18 -3.62

Bionano Genomics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.18 -2.66 -2.28 -3.12 -3.62

Competitive Comparison of Bionano Genomics's Beneish M-Score

For the Medical Instruments & Supplies subindustry, Bionano Genomics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bionano Genomics's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bionano Genomics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Bionano Genomics's Beneish M-Score falls into.



Bionano Genomics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Bionano Genomics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9921+0.528 * 0.8075+0.404 * 0.4945+0.892 * 1.299+0.115 * 0.8458
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8124+4.679 * -0.068348-0.327 * 3.4162
=-3.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $9.66 Mil.
Revenue was 10.721 + 9.318 + 8.662 + 7.415 = $36.12 Mil.
Gross Profit was 2.438 + 2.749 + 2.308 + 2.07 = $9.57 Mil.
Total Current Assets was $140.12 Mil.
Total Assets was $214.40 Mil.
Property, Plant and Equipment(Net PPE) was $32.48 Mil.
Depreciation, Depletion and Amortization(DDA) was $13.91 Mil.
Selling, General, & Admin. Expense(SGA) was $93.50 Mil.
Total Current Liabilities was $100.03 Mil.
Long-Term Debt & Capital Lease Obligation was $7.18 Mil.
Net Income was -43.891 + -112.566 + -38.912 + -37.124 = $-232.49 Mil.
Non Operating Income was -15.265 + -77.254 + -0.256 + 0.117 = $-92.66 Mil.
Cash Flow from Operations was -29.779 + -26.293 + -36.696 + -32.413 = $-125.18 Mil.
Total Receivables was $7.50 Mil.
Revenue was 8.215 + 7.221 + 6.67 + 5.696 = $27.80 Mil.
Gross Profit was 1.805 + 1.809 + 1.471 + 0.861 = $5.95 Mil.
Total Current Assets was $157.30 Mil.
Total Assets was $307.50 Mil.
Property, Plant and Equipment(Net PPE) was $28.96 Mil.
Depreciation, Depletion and Amortization(DDA) was $9.84 Mil.
Selling, General, & Admin. Expense(SGA) was $88.60 Mil.
Total Current Liabilities was $35.88 Mil.
Long-Term Debt & Capital Lease Obligation was $9.12 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(9.661 / 36.116) / (7.496 / 27.802)
=0.267499 / 0.269621
=0.9921

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(5.946 / 27.802) / (9.565 / 36.116)
=0.21387 / 0.264841
=0.8075

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (140.118 + 32.481) / 214.404) / (1 - (157.298 + 28.958) / 307.502)
=0.194982 / 0.394293
=0.4945

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=36.116 / 27.802
=1.299

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(9.84 / (9.84 + 28.958)) / (13.912 / (13.912 + 32.481))
=0.253621 / 0.299873
=0.8458

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(93.498 / 36.116) / (88.597 / 27.802)
=2.588825 / 3.186713
=0.8124

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((7.175 + 100.028) / 214.404) / ((9.123 + 35.884) / 307.502)
=0.500005 / 0.146363
=3.4162

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-232.493 - -92.658 - -125.181) / 214.404
=-0.068348

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Bionano Genomics has a M-score of -3.62 suggests that the company is unlikely to be a manipulator.


Bionano Genomics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Bionano Genomics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Bionano Genomics (Bionano Genomics) Business Description

Traded in Other Exchanges
Address
9540 Towne Centre Drive, Suite 100, San Diego, CA, USA, 92121
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas.
Executives
Gulsen Kama officer: Chief Financial Officer C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Hannah Mamuszka director C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
R. Erik Holmlin director, officer: President and CEO 4088 COMMERCIAL AVE., NORTHBROOK IL 60062
Christopher P. Stewart officer: Chief Financial Officer C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Jonathan V. Dixon officer: General Counsel C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Yvonne Linney director C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
David L Barker director 9885 TOWNE CENTRE DR, SAN DIEGO CA 92121
Aleksandar Rajkovic director 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Vincent Jung-fai Wong director C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Soheil Shams officer: Chief Informatics Officer C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Richard Shippy officer: Chief Business Officer C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Robert J Priar officer: Chief Commercial Officer C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Alka Chaubey officer: Chief Medical Officer C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Heather Adams officer: Chief Administrative Officer C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Kristiina Md Vuori director C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011

Bionano Genomics (Bionano Genomics) Headlines

From GuruFocus

Bionano Announces Results from its Annual Meeting of Stockholders

By sperokesalga sperokesalga 06-15-2023